About this item:

132 Views | 65 Downloads

Author Notes:

Address correspondence to: Davida F. Kruger, MSN, APNBC, BCADM, Division of Endocrinology, Diabetes, and Bone Disorders, Henry Ford Health System, 3031 West Grand Boulevard, Suite 800, Detroit, MI 48202, dkruger1@hfhs.org

The authors thank Christopher G. Parkin, CGParkin Communications, Inc., for his thoughtful assistance in developing this article.

J.E.A. reports receiving speaker fees from Abbott Diabetes Care. J.R.G. III has served on advisory boards and/or speaker bureaus for Abbott Diabetes Care.

D.F.K. has served on advisory boards and/or speaker bureaus for Dexcom and Abbott Diabetes Care, and her institution has received research support from Dexcom.

Subject:

Research Funding:

Abbott Diabetes Care provided funding for editorial assistance in developing this article.

Keywords:

  • insulin delivery systems
  • glucose monitoring technology
  • diabetes
  • financial burden
  • complications
  • poor control
  • human error
  • continuous glucose monitoring
  • type 1 diabetes

Current Eligibility Requirements for CGM Coverage Are Harmful, Costly, and Unjustified

Tools:

Journal Title:

Diabetes Technology & Therapeutics

Volume:

Volume 22, Number 3

Publisher:

, Pages 169-173

Type of Work:

Article | Final Publisher PDF

Abstract:

Despite ongoing advances in medications, insulin delivery systems, and glucose monitoring technologies, diabetes control remains suboptimal in many individuals with this disease. In addition to the clinical consequences resulting from poor control is the ever-increasing financial burden on individuals, health systems, and society.

Copyright information:

© John E. Anderson, et al., 2020; Published by Mary Ann Liebert, Inc.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote